Capital solutions for every stage of growth
In collaboration with Mizuho's product specialists and Financial Sponsors team, we have led high-profile M&A and acquisition-financing deals as well as growth-stage financings. We provide clients a full suite of capabilities, including debt and equity offerings, leveraged finance, risk-focused derivative solutions, strategic advisory, corporate finance and working capital solutions.
Highlights
- Provider of debt and equity financing for some of the largest acquisitions across healthcare including Danaher’s purchase of GE BioPharma, Thermo Fisher Scientific’s acquisition of Qiagen NV, and AbbVie’s acquisition of Allergan plc
- Strong equity franchise acting as bookrunner on IPOs of PPD, BridgeBio and Evolus and Secondary / Convertible Financings for Assembly BioSciences, Cytokinetics, Wave Life Sciences
- Active M&A advisory business with recent buyside and sellside transactions for Gilead Sciences Inc. and Halo Pharmaceuticals Inc.
- Provider of credit to support acquisition financings for Bristol Myers Squibb, Cigna, Danaher, Mylan and Teva Pharmaceuticals
- Strong partnership with Financial Sponsors Group including go-private financings for Cambrex, AMRI and Envision
- Strong record of providing clients with Deal Contingent Risk Solutions through partnership with our Risk Solutions and integrated M&A teams
Industry Expertise
-
Biotech -
Pharma -
Medical Devices -
Healthcare Services
-
Category: Research
COVID Collaborations Spotlight the Symbiotic Nature Between Pharma and Biotech
-
Category: Expert Opinions
Why Biotech is Poised for Continued Strength
-
Category: Expert Opinions
A 2019 Healthcare Market Recap and 2020 Forecast by Mizuho Americas
-
Category: Research
Managed Care Investors Must Manage the Political Tradewinds
-
Category: Research
Dry Eye on the Rise
-
Category: Research
Equity Research Analyst Mara Goldstein on the Evolving Immuno-Oncology Sector